EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Iodine avidity in papillary and poorly differentiated thyroid cancer is predicted by immunohistochemical and molecular work-up

Joachim N Nilsson iD, Jonathan Siikanen iD, Vincenzo Condello iD, Kenbugul Jatta iD, Ravi Saini, Christel Hedman iD, Catharina Ihre Lundgren iD, C Christofer Juhlin iD

European Thyroid Journal · 28.07.2023 · 12 (4)

DOI: 10.1530/etj-23-0099 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Thyroid Journal, erschienen am 28.07.2023. Verfasst von Joachim N Nilsson und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden. Hauptthemen laut MEDLINE: Iodine, Carcinoma, Papillary, Thyroid Neoplasms, Adenocarcinoma. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Successful radioiodine treatment of differentiated thyroid cancer requires iodine avidity: that is, the concentration and retention of iodine in cancer tissue. Several parameters have previously been linked with lower iodine avidity. However, a comprehensive analysis of which factors best predict iodine avidity status, and the magnitude of their impact, is lacking.

Methods

Quantitative measurements of iodine avidity in surgical specimens (primary tumour and lymph node metastases) of 28 patients were compared to immunohistochemical expression of the thyroid-stimulating hormone receptor, thyroid peroxidase (TPO), pendrin, sodium–iodide symporter (NIS) and mutational status of BRAF and the TERT promoter. Regression analysis was used to identify independent predictors of poor iodine avidity.

Results

Mutations in BRAF and the TERT promoter were significantly associated with lower iodine avidity for lymph node metastases (18-fold and 10-fold, respectively). Membranous NIS localisation was found only in two cases but was significantly associated with high iodine avidity. TPO expression was significantly correlated with iodine avidity ( r = 0.44). The multivariable modelling showed that tumour tissue localisation (primary tumour or lymph node metastasis), histological subtype, TPO and NIS expression and TERT promoter mutation were each independent predictors of iodine avidity that could explain 68% of the observed variation of iodine avidity.

Conclusions

A model based on histological subtype, TPO and NIS expression and TERT promoter mutation, all evaluated on initial surgical material, can predict iodine avidity in thyroid cancer tissue ahead of treatment. This could inform early adaptation with respect to expected treatment effect.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

IodineCarcinoma, PapillaryThyroid NeoplasmsAdenocarcinomaHumansIodine RadioisotopesLymphatic MetastasisProto-Oncogene Proteins B-raf

Stichwörter der Autor:innen

NISTERTTPOiodine aviditythyroid cancer

Substanzen

IodineIodine RadioisotopesProto-Oncogene Proteins B-raf

Autor:innen und Institutionen

  • Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.
  • Department of Medical Radiation Physics and Nuclear Medicine, Karolinska University Hospital, Stockholm, Sweden.
  • Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
  • Department of Pathology and Cancer Diagnostics, Karolinska University Hospital, Stockholm, Sweden.
  • Stockholms Sjukhem Foundation's Research and Development Department, Stockholm, Sweden.
  • Department of Clinical Sciences Lund, Lund University, Lund, Sweden.

ORCID-Profile: Joachim N Nilsson, Jonathan Siikanen, Vincenzo Condello, Kenbugul Jatta, Christel Hedman, Catharina Ihre Lundgren, C Christofer Juhlin

Zitieren

APA

Nilsson, J. N., Siikanen, J., Condello, V., Jatta, K., Saini, R., Hedman, C., Ihre Lundgren, C., & Juhlin, C. C. (2023). Iodine avidity in papillary and poorly differentiated thyroid cancer is predicted by immunohistochemical and molecular work-up. European Thyroid Journal, 12(4). https://doi.org/10.1530/etj-23-0099

Vancouver

Nilsson JN, Siikanen J, Condello V, Jatta K, Saini R, Hedman C, et al. Iodine avidity in papillary and poorly differentiated thyroid cancer is predicted by immunohistochemical and molecular work-up. European Thyroid Journal. 2023;12(4). doi:10.1530/etj-23-0099

BibTeX
@article{Nilsson2023,
  author = {Nilsson, Joachim N and Siikanen, Jonathan and Condello, Vincenzo and Jatta, Kenbugul and Saini, Ravi and Hedman, Christel and Ihre Lundgren, Catharina and Juhlin, C Christofer},
  title = {Iodine avidity in papillary and poorly differentiated thyroid cancer is predicted by immunohistochemical and molecular work-up},
  journal = {European Thyroid Journal},
  year = {2023},
  volume = {12},
  number = {4},
  doi = {10.1530/etj-23-0099}
}
Kostenlos starten →